Obesity drug market surges

The hottest corner of pharma is no longer cancer or cholesterol. It is obesity, where companies are racing to sell drugs that can be taken for years by tens of millions of people, and industry trackers now count more than 80 drugmakers in the clinical pipeline. (openpr.com) The rush started because the first wave of drugs showed weight loss on a scale that older medicines rarely matched. Wegovy, Novo Nordisk’s semaglutide shot, is approved in the United States for long-term weight reduction in adults with obesity and in adults with overweight plus at least one related condition. (accessdata.fda.gov) Zepbound, Eli Lilly’s tirzepatide shot, widened the market again because it works on two hormone pathways instead of one. Its United States label says it is used with a reduced-calorie diet and more physical activity for adults with obesity or adults with overweight plus a related condition. (pi.lilly.com) Demand is not coming out of nowhere. The Centers for Disease Control and Prevention says United States adult obesity prevalence rose from 30.5 percent in 1999-2000 to 41.9 percent in 2017-March 2020, and severe obesity nearly doubled to 9.2 percent over the same span. (cdc.gov) The global picture is even bigger. The World Health Organization says that in 2022, 890 million adults were living with obesity, adult obesity had more than doubled since 1990, and 1 in 8 people worldwide were living with obesity. (who.int) That is why the story is shifting from one blockbuster drug to a whole treatment industry. One market forecast now projects a 12.8 percent compound annual growth rate for weight-loss and obesity-management services, with North America and Asia-Pacific leading spending. (prnewswire.com) The next fight is not just over who has the best injection. Novo Nordisk’s United States prescribing information now includes a Wegovy tablet, turning a weekly shot into a daily pill option for some patients and giving the company a way to reach people who do not want needles. (accessdata.fda.gov) Price is becoming a weapon too. Eli Lilly’s Zepbound savings page advertises self-pay access starting at $299 for a one-month prescription of the KwikPen for eligible patients, which shows how manufacturers are trying to pull in people whose insurance still will not cover obesity treatment. (zepbound.lilly.com) Supply used to be the choke point, and companies are still spending heavily to avoid running out. Novo Nordisk’s investor site now centers manufacturing and launch updates alongside its financial results, because in this market a factory expansion can move sales almost as much as a clinical trial. (novonordisk.com) The field is also moving beyond weight alone. Wegovy’s United States label includes a heart-risk reduction use in adults with established cardiovascular disease and obesity or overweight, and Zepbound’s label includes treatment for moderate to severe obstructive sleep apnea in adults with obesity. (accessdata.fda.gov 1) (accessdata.fda.gov 2) That changes the business math. A drug that starts as a weight-loss product and then adds heart disease, liver disease, or sleep apnea can move from a cosmetic debate to a mainstream chronic-care budget line, which is why so many companies are piling into trials now. (accessdata.fda.gov) (openpr.com) What looked like a single drug boom in 2023 now looks more like the buildout of a new medical category in 2026: more companies, more formulations, more disease claims, and a bigger push to turn obesity care into something that looks like diabetes or blood-pressure treatment rather than a short-term diet fix. (openpr.com) (prnewswire.com)